[Form 4] Jazz Pharmaceuticals, Inc. Insider Trading Activity
Kenneth W. O'Keefe, identified as a director of Jazz Pharmaceuticals (JAZZ), reported both a grant of restricted stock units and a sale of ordinary shares. On 08/07/2025 he was granted 3,507 restricted stock units under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; each unit represents a contingent right to one ordinary share and, subject to continuous service and conditions, vests in full on July 24, 2026. The next day, 08/08/2025, he sold 1,805 shares at $111.2502 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units. Following these transactions the reporting person beneficially owns 28,672 shares directly, and 4,445 shares indirectly through The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which he is trustee and beneficiary.
Kenneth W. O'Keefe, identificato come membro del consiglio di amministrazione di Jazz Pharmaceuticals (JAZZ), ha comunicato sia l'assegnazione di restricted stock units sia la vendita di azioni ordinarie. In data 08/07/2025 gli sono state assegnate 3,507 restricted stock units nell'ambito dell'Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; ogni unit脿 rappresenta il diritto condizionato a una azione ordinaria e, soggetta al servizio continuativo e alle condizioni previste, matura integralmente il 24 luglio 2026. Il giorno successivo, 08/08/2025, ha venduto 1,805 azioni a $111.2502 per azione per adempiere agli obblighi fiscali derivanti dalla maturazione di unit脿 precedentemente assegnate. A seguito di tali operazioni, la persona che ha presentato la segnalazione detiene beneficiariamente 28,672 azioni direttamente e 4,445 azioni indirettamente tramite The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, di cui 猫 trustee e beneficiario.
Kenneth W. O'Keefe, identificado como director de Jazz Pharmaceuticals (JAZZ), inform贸 tanto la concesi贸n de unidades restringidas como la venta de acciones ordinarias. El 08/07/2025 se le otorgaron 3,507 unidades restringidas en virtud del Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; cada unidad representa el derecho contingente a una acci贸n ordinaria y, sujeto a servicio continuado y a las condiciones aplicables, se consolida en su totalidad el 24 de julio de 2026. Al d铆a siguiente, 08/08/2025, vendi贸 1,805 acciones a $111.2502 por acci贸n para satisfacer obligaciones fiscales derivadas del vencimiento de unidades restringidas previamente concedidas. Tras estas operaciones, la persona declarante posee beneficiariamente 28,672 acciones directamente y 4,445 acciones indirectamente a trav茅s de The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, del que es fiduciario y beneficiario.
Kenneth W. O'Keefe電� Jazz Pharmaceuticals(JAZZ)鞚� 鞚挫偓搿� 霌膘灛霅橃柎 鞛堨溂氅�, 鞝滍暅欤检嫕雼渼鞚� 攵�鞐檧 氤错喌欤� 毵り皝鞚� 氇憪 氤搓碃頄堨姷雼堧嫟. 08/07/2025 鞛愲 攴鸽姅 Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan鞐� 霐半澕 3,507臧滌潣 鞝滍暅欤检嫕雼渼毳� 攵�鞐皼鞎橃溂氅�, 臧� 雼渼電� 1欤检潣 氤错喌欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 雮橅儉雮搓碃 鞐办啀鞝侅澑 攴茧 氚� 旮绊儉 臁瓣贝 於╈” 鞁� 2026雲� 7鞗� 24鞚检棎 鞝勲秬 頇曥爼霅╇媹雼�. 雼れ潓 雮犾澑 08/08/2025鞐愲姅 鞚挫爠鞐� 攵�鞐悳 鞝滍暅欤检嫕雼渼鞚� 頇曥爼鞙茧 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 欤茧嫻 $111.2502鞐� 1,805欤�毳� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 氤搓碃鞚胳潃 歆侅爲 28,672欤�毳�, 攴鸽Μ瓿� 鞛愳嫚鞚� 靾橅儊鞛愳澊鞛� 靾橅槣鞛愳澑 The Kenneth W. O'Keefe Trust U/A/D 2/12/1997鞚� 韱淀暣 臧勳爲鞝侅溂搿� 4,445欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
Kenneth W. O'Keefe, identifi茅 en tant qu'administrateur de Jazz Pharmaceuticals (JAZZ), a d茅clar茅 脿 la fois l'attribution d'unit茅s d'actions restreintes et la vente d'actions ordinaires. Le 08/07/2025, il s'est vu attribuer 3,507 unit茅s d'actions restreintes dans le cadre de l'Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan ; chaque unit茅 repr茅sente un droit conditionnel sur une action ordinaire et, sous r茅serve d'une pr茅sence continue et des conditions applicables, devient pleinement acquise le 24 juillet 2026. Le lendemain, 08/08/2025, il a vendu 1,805 actions au prix de $111.2502 par action pour couvrir des obligations fiscales li茅es 脿 l'acquisition des unit茅s restreintes pr茅c茅demment attribu茅es. Suite 脿 ces op茅rations, la personne d茅clarant b茅n茅ficie de la propri茅t茅 effective de 28,672 actions directement et de 4,445 actions indirectement via The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, dont il est le fiduciaire et le b茅n茅ficiaire.
Kenneth W. O'Keefe, als Direktor von Jazz Pharmaceuticals (JAZZ) genannt, meldete sowohl die Gew盲hrung von Restricted Stock Units als auch den Verkauf von Stammaktien. Am 08/07/2025 wurden ihm 3,507 Restricted Stock Units gem盲脽 dem Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan zugeteilt; jede Einheit repr盲sentiert ein bedingtes Recht auf eine Stammaktie und, vorbehaltlich fortlaufender Dienstleistung und weiterer Bedingungen, f盲llt am 24. Juli 2026 vollst盲ndig frei. Am folgenden Tag, dem 08/08/2025, verkaufte er 1,805 Aktien zu $111.2502 je Aktie, um Steuerverpflichtungen infolge der Vesting-Ereignisse zuvor gew盲hrter Restricted Stock Units zu erf眉llen. Nach diesen Transaktionen h盲lt die meldende Person wirtschaftlich 28,672 Aktien direkt und 4,445 Aktien indirekt 眉ber The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, dessen Treuh盲nder und Beg眉nstigter er ist.
- 3,507 restricted stock units granted to the director under the Issuer's 2007 Non-Employee Directors Stock Award Plan, aligning interests with shareholders
- Vesting date disclosed: units vest in full on July 24, 2026 subject to continuous service, providing clarity on timing of potential future issuance
- Continued insider ownership: reporting person holds 28,672 shares directly after transactions and 4,445 shares indirectly via trust
- None.
Insights
TL;DR Director received 3,507 RSUs and completed a tax-related sale of 1,805 shares; holdings remain concentrated and aligned.
The grant of 3,507 restricted stock units to a non-employee director is a routine equity-compensation action that aligns the director's interests with shareholders while deferring actual share issuance until vesting on July 24, 2026. The subsequent sale of 1,805 shares at $111.2502 is explicitly described as a transaction to satisfy tax obligations from prior vesting and therefore does not indicate opportunistic disposition of core holdings. Beneficial ownership after the reported transactions stands at 28,672 direct shares plus 4,445 indirect shares, preserving meaningful insider exposure to equity performance. Impact on capital structure or dilution is not indicated in this form.
TL;DR Compensation and tax-related sale are standard governance events; trustee status confirms continued economic interest.
The reported RSU award is granted under the company's non-employee directors plan and vests contingent on continued service, which is consistent with standard governance practices for aligning independent directors with shareholder outcomes. The sale identified by the filer as executed to satisfy tax obligations is a common mechanism following vesting and is not presented as a voluntary portfolio reallocation. The filing also discloses indirect ownership via a trust (4,445 shares), where the reporting person is trustee and beneficiary, reinforcing ongoing economic exposure. Material governance or control changes are not shown.
Kenneth W. O'Keefe, identificato come membro del consiglio di amministrazione di Jazz Pharmaceuticals (JAZZ), ha comunicato sia l'assegnazione di restricted stock units sia la vendita di azioni ordinarie. In data 08/07/2025 gli sono state assegnate 3,507 restricted stock units nell'ambito dell'Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; ogni unit脿 rappresenta il diritto condizionato a una azione ordinaria e, soggetta al servizio continuativo e alle condizioni previste, matura integralmente il 24 luglio 2026. Il giorno successivo, 08/08/2025, ha venduto 1,805 azioni a $111.2502 per azione per adempiere agli obblighi fiscali derivanti dalla maturazione di unit脿 precedentemente assegnate. A seguito di tali operazioni, la persona che ha presentato la segnalazione detiene beneficiariamente 28,672 azioni direttamente e 4,445 azioni indirettamente tramite The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, di cui 猫 trustee e beneficiario.
Kenneth W. O'Keefe, identificado como director de Jazz Pharmaceuticals (JAZZ), inform贸 tanto la concesi贸n de unidades restringidas como la venta de acciones ordinarias. El 08/07/2025 se le otorgaron 3,507 unidades restringidas en virtud del Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; cada unidad representa el derecho contingente a una acci贸n ordinaria y, sujeto a servicio continuado y a las condiciones aplicables, se consolida en su totalidad el 24 de julio de 2026. Al d铆a siguiente, 08/08/2025, vendi贸 1,805 acciones a $111.2502 por acci贸n para satisfacer obligaciones fiscales derivadas del vencimiento de unidades restringidas previamente concedidas. Tras estas operaciones, la persona declarante posee beneficiariamente 28,672 acciones directamente y 4,445 acciones indirectamente a trav茅s de The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, del que es fiduciario y beneficiario.
Kenneth W. O'Keefe電� Jazz Pharmaceuticals(JAZZ)鞚� 鞚挫偓搿� 霌膘灛霅橃柎 鞛堨溂氅�, 鞝滍暅欤检嫕雼渼鞚� 攵�鞐檧 氤错喌欤� 毵り皝鞚� 氇憪 氤搓碃頄堨姷雼堧嫟. 08/07/2025 鞛愲 攴鸽姅 Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan鞐� 霐半澕 3,507臧滌潣 鞝滍暅欤检嫕雼渼毳� 攵�鞐皼鞎橃溂氅�, 臧� 雼渼電� 1欤检潣 氤错喌欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 雮橅儉雮搓碃 鞐办啀鞝侅澑 攴茧 氚� 旮绊儉 臁瓣贝 於╈” 鞁� 2026雲� 7鞗� 24鞚检棎 鞝勲秬 頇曥爼霅╇媹雼�. 雼れ潓 雮犾澑 08/08/2025鞐愲姅 鞚挫爠鞐� 攵�鞐悳 鞝滍暅欤检嫕雼渼鞚� 頇曥爼鞙茧 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 欤茧嫻 $111.2502鞐� 1,805欤�毳� 毵る弰頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 氤搓碃鞚胳潃 歆侅爲 28,672欤�毳�, 攴鸽Μ瓿� 鞛愳嫚鞚� 靾橅儊鞛愳澊鞛� 靾橅槣鞛愳澑 The Kenneth W. O'Keefe Trust U/A/D 2/12/1997鞚� 韱淀暣 臧勳爲鞝侅溂搿� 4,445欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
Kenneth W. O'Keefe, identifi茅 en tant qu'administrateur de Jazz Pharmaceuticals (JAZZ), a d茅clar茅 脿 la fois l'attribution d'unit茅s d'actions restreintes et la vente d'actions ordinaires. Le 08/07/2025, il s'est vu attribuer 3,507 unit茅s d'actions restreintes dans le cadre de l'Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan ; chaque unit茅 repr茅sente un droit conditionnel sur une action ordinaire et, sous r茅serve d'une pr茅sence continue et des conditions applicables, devient pleinement acquise le 24 juillet 2026. Le lendemain, 08/08/2025, il a vendu 1,805 actions au prix de $111.2502 par action pour couvrir des obligations fiscales li茅es 脿 l'acquisition des unit茅s restreintes pr茅c茅demment attribu茅es. Suite 脿 ces op茅rations, la personne d茅clarant b茅n茅ficie de la propri茅t茅 effective de 28,672 actions directement et de 4,445 actions indirectement via The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, dont il est le fiduciaire et le b茅n茅ficiaire.
Kenneth W. O'Keefe, als Direktor von Jazz Pharmaceuticals (JAZZ) genannt, meldete sowohl die Gew盲hrung von Restricted Stock Units als auch den Verkauf von Stammaktien. Am 08/07/2025 wurden ihm 3,507 Restricted Stock Units gem盲脽 dem Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan zugeteilt; jede Einheit repr盲sentiert ein bedingtes Recht auf eine Stammaktie und, vorbehaltlich fortlaufender Dienstleistung und weiterer Bedingungen, f盲llt am 24. Juli 2026 vollst盲ndig frei. Am folgenden Tag, dem 08/08/2025, verkaufte er 1,805 Aktien zu $111.2502 je Aktie, um Steuerverpflichtungen infolge der Vesting-Ereignisse zuvor gew盲hrter Restricted Stock Units zu erf眉llen. Nach diesen Transaktionen h盲lt die meldende Person wirtschaftlich 28,672 Aktien direkt und 4,445 Aktien indirekt 眉ber The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, dessen Treuh盲nder und Beg眉nstigter er ist.
FAQ
What transactions did Kenneth W. O'Keefe report for JAZZ?
When do the granted restricted stock units vest?
How many JAZZ shares does Kenneth O'Keefe beneficially own after these transactions?
What was the purpose of the 1,805-share sale reported on 08/08/2025?
Under which plan were the restricted stock units granted?
